Ajanta Pharma releases pledge on 2.33 million shares held by Ravi Agrawal Trust

What Ajanta Pharma announced

Ajanta Pharma Ltd filed a disclosure with the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) on 19 June 2026, reporting that promoter Ravi Agrawal Trust has released the pledge on 2,326,289 equity shares of the company. The release was effected on 16 June 2026 and is classified under the “Excess Pledge” reason, meaning the promoter chose to free shares that were previously pledged as collateral.

The filing cites Regulation 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, which require promoters to inform the exchanges and the target company whenever an encumbrance on shares is created, released or invoked.

Details of the pledge release

• Promoter involved: Ravi Agrawal, trustee of the Ravi Agrawal Trust.
• Number of shares released: 2,326,289 shares (approximately 4.05% of Ajanta Pharma’s total share capital).
• Date of release: 16 June 2026.
• Reason for release: Excess pledge – the promoter deemed the pledged amount higher than required for its financing needs.
• Lenders affected: The release impacted pledges held by several lenders, including Adity Birla Capital Ltd, Bajaj Finance Ltd, HSBC Direct Invest Financial Services Pvt Ltd and others. The table in the filing lists individual release amounts per lender, totalling the 2.33 million shares.

The promoter’s letter, signed digitally by Ravi Purushottam Agrawal, confirms that the pledge release has been communicated to the company secretary and that the exchange has been notified.

Key facts at a glance

Why this matters for investors

The release of pledged shares reduces the proportion of Ajanta Pharma’s equity that is encumbered as collateral. A lower pledged percentage can be viewed positively by investors because it diminishes the risk that a large portion of the promoter’s holdings could be forced to be sold in the event of a default by the lender. However, the filing does not disclose any change in the promoter’s overall shareholding; it only reports the reduction in the encumbered portion.

For shareholders, the key implication is a potential improvement in the company’s governance perception, as promoters with fewer pledged shares are often seen as having stronger skin in the game. The disclosure also satisfies regulatory transparency requirements, ensuring that the market is aware of changes in share encumbrance.

Conclusion

Ajanta Pharma’s filing confirms that the Ravi Agrawal Trust has released pledge on 2.33 million shares, lowering the pledged share ratio to 4.05 % of total capital. The action was taken on 16 June 2026 and reported on 19 June 2026 under SEBI’s SAST regulations. No further regulatory approvals are required for the release, and the company’s shareholding structure remains unchanged apart from the reduction in encumbrance.